Is Wanbury a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Wanbury Ltd is a good quality company .

Is Wanbury undervalued or overvalued?

The key valuation ratios of Wanbury Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Wanbury share price return in the past 10 years?

Wanbury Ltd share price has appreciated 16.4% annually (CAGR) over the past ten years.

Is Wanbury a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Wanbury Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

Wanbury Ltd - Stock Valuation and Financial Performance

Name: Wanbury
Brand: Wanbury

BSE: 524212 | NSE: WANBURY | Pharmaceuticals & Drugs | Small Cap

Place order

Wanbury Share Price

₹211 -11.00 -4.95%
as on 21-Nov'24 16:59

10 Year X-Ray of Wanbury:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	12%	13.2%	59.5%	-1.5%	26.9%	204.9%	28.2%	206.3%	17.7%	61.6%	-
Value Creation Index ⓘ	NA	NA	3.3	NA	NA	13.6	NA	13.7	NA	3.4	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	500	423	434	371	391	367	393	511	500	576	577
Sales YoY Gr.	-	-15.3%	2.5%	-14.5%	5.5%	-6.1%	6.8%	30.2%	-2.3%	15.2%	-
Adj EPS ⓘ	-1.1	-3.3	24.9	-13.9	-10.4	2.5	-4.8	11	-2.9	8.8	8.4
YoY Gr.	-	NA	NA	-155.7%	NA	NA	-293.9%	NA	-126.5%	NA	-
BVPS (₹) ⓘ	-193	-99.3	-54.9	-67.2	-77.5	-47.2	-52.4	0.3	-2.8	6.4	11.8
Adj Net Profit ⓘ	-2.2	-6.6	57.8	-32.9	-24.6	6.2	-11.9	35.8	-9.5	28.8	27
Cash Flow from Ops. ⓘ	80.1	43.2	43.4	32.5	29.7	44.1	16.7	40.5	19.8	4	-
Debt/CF from Ops. ⓘ	9.5	8.7	6.2	6.8	7.8	3.7	9.6	1.7	3.2	27.4	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	1.6%	8%	13.6%	15.2%
Adj EPS ⓘ	NA	NA	NA	NA
BVPSⓘ	NA	NA	NA	NA
Share Price	16.4%	65.6%	42%	125.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	0.7	4	-39.8	23	14.4	-4.1	9.6	-55.7	374.1	278	91.6
Op. Profit Mgn % ⓘ	8.6	7.9	4.3	-18.2	3.6	-5.9	4.3	6.4	4.8	12.2	12.2
Net Profit Mgn % ⓘ	-0.4	-1.6	13.3	-8.9	-6.3	1.7	-3	7	-1.9	5	4.8
Debt to Equity ⓘ	-2	-1.9	-2.1	-1.4	-1.3	-1.4	-1.2	71.5	-7.1	5.2	3.1
Working Cap Days ⓘ	295	162	159	127	74	86	78	84	97	89	52
Cash Conv. Cycle ⓘ	15	2	-17	-51	-59	-81	-77	-60	-68	-52	-13

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 13.61%

Debt to equity has declined versus last 3 years average to 5.21

Return on Equity has declined versus last 3 years average to 91.60%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 5.43%

Latest Financials - Wanbury Ltd.

	Standalone	Consolidated
TTM EPS (₹)	8.4	16.2
TTM Sales (₹ Cr.)	577	577
BVPS (₹.) ⓘ	11.8	11.8
Reserves (₹ Cr.) ⓘ	6	6
P/BV ⓘ	18.77	18.77
PE ⓘ	26.54	13.73

From the Market
52 Week Low / High (₹)	91.00 / 291.00
All Time Low / High (₹)	0.85 / 291.00
Market Cap (₹ Cr.)	727
Equity (₹ Cr.)	32.8
Face Value (₹)	10
Industry PE ⓘ	43

Management X-Ray of Wanbury:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

76.74

0.00

76.74

71.05

76.74

* Pledged shares as % of Promoter's holding (%)

Valuation of Wanbury

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Wanbury

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	250	423	434	371	391	367	393	511	500	576
Operating Expenses ⓘ	228	391	415	439	378	389	377	479	477	506
Manufacturing Costs	16	31	34	25	22	29	27	31	32	38
Material Costs	119	182	197	174	196	176	221	300	303	303
Employee Cost	40	85	88	87	76	67	64	75	81	87
Other Costs ⓘ	54	92	97	152	84	117	64	73	60	78
Operating Profit ⓘ	21	32	19	-68	13	-22	16	32	23	70
Operating Profit Margin (%)	8.6%	7.7%	4.3%	-18.3%	3.4%	-5.9%	4.0%	6.2%	4.6%	12.2%
Other Income ⓘ	6	1	90	77	12	46	5	5	1	3
Interest ⓘ	19	32	36	31	40	33	23	21	21	29
Depreciation ⓘ	5	9	10	10	10	10	10	11	12	13
Exceptional Items ⓘ	0	0	0	0	0	83	0	76	-1	0
Profit Before Tax ⓘ	4	-7	62	-32	-25	65	-12	81	-10	31
Tax ⓘ	1	0	0	0	0	0	0	0	0	0
Profit After Tax	3	-7	62	-32	-25	64	-13	81	-10	30
PAT Margin (%)	1.3%	-1.7%	14.3%	-8.6%	-6.3%	17.5%	-3.2%	15.9%	-2.1%	5.3%
Adjusted EPS (₹)	1.6	-3.5	26.7	-13.5	-10.5	25.8	-5.0	24.9	-3.2	9.3
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	-168	-175	-127	-159	-184	-118	-131	1	-9	21
Share Capital ⓘ	20	20	23	24	24	25	25	33	33	33
Reserves ⓘ	-188	-195	-151	-183	-208	-143	-156	-31	-42	-12
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	348	322	217	182	208	124	88	13	13	97
Long Term Debt	270	231	154	99	123	100	72	0	0	82
Short Term Debt	78	91	63	83	85	25	16	13	13	15
Trade Payables	99	86	140	83	112	121	133	179	148	163
Others Liabilities ⓘ	116	155	178	163	145	146	191	152	144	57
Total Liabilities ⓘ	394	386	407	268	281	274	282	345	296	338
Fixed Assets
Gross Block	306	326	197	199	202	203	216	227	239	248
Accumulated Depreciation	142	145	10	20	30	39	49	60	72	82
Net Fixed Assetsⓘ	164	180	186	178	172	164	167	167	167	167
CWIP ⓘ	19	14	10	10	9	14	11	2	2	3
Investmentsⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	34	35	34	13	19	12	25	50	22	36
Trade Receivables	99	75	85	29	44	51	34	63	69	89
Cash Equivalents	12	7	9	6	5	17	12	25	4	6
Others Assetsⓘ	68	75	83	31	31	16	33	38	33	37
Total Assets ⓘ	394	386	407	268	281	274	282	345	296	338

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	40	43	43	32	30	44	17	41	20	4
PBT ⓘ	4	-7	62	-32	-25	65	-12	81	-10	31
Adjustment ⓘ	23	48	-37	40	43	-41	33	-44	37	42
Changes in Working Capital ⓘ	13	2	18	26	12	21	-3	3	-7	-68
Tax Paid ⓘ	0	0	0	-1	0	0	-1	0	0	0
Cash Flow From Investing Activity ⓘ	-5	-20	-13	-1	-3	64	8	1	-9	-17
Capex	-5	-21	-15	-3	-5	-8	-4	1	-9	-14
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	2	2	1	2	71	12	-1	1	-3
Cash Flow From Financing Activityⓘ	-30	-28	-27	-33	-27	-108	-17	-29	-32	15
Net Proceeds from Shares ⓘ	0	12	0	0	0	0	0	50	0	0
Net Proceeds from Borrowing ⓘ	-12	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-21	-23	-16	-7	-11	-11	-7	-15	-17	-35
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	4	-17	-11	-27	-15	-97	-11	-63	-15	49
Net Cash Flow ⓘ	5	-5	3	-2	0	0	7	13	-21	2

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0	N/A	502.76
ROCE (%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	206.26	N/A	61.61
Asset Turnover Ratio	0.64	1.11	1.12	1.17	1.51	1.34	1.42	1.64	1.59	1.83
PAT to CFO Conversion(x)	13.33	N/A	0.69	N/A	N/A	0.69	N/A	0.51	N/A	0.13
Working Capital Days
Receivable Days	145	73	66	53	32	47	39	35	47	50
Inventory Days	49	29	28	22	14	16	17	26	26	18
Payable Days	294	185	209	233	181	242	210	190	197	188

Wanbury Ltd Stock News

Wanbury Ltd FAQs

What is the share price of Wanbury?

Company share prices are keep on changing according to the market conditions. The closing price of Wanbury on 21-Nov-2024 16:59 is ₹211.0.

What is the market cap of Wanbury?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Wanbury stood at ₹727.3.

What is the P/E ratio of Wanbury?

The latest P/E ratio of Wanbury as of 21-Nov-2024 16:59 is 26.54.

What is the P/B ratio of Wanbury?

The latest P/B ratio of Wanbury as of 21-Nov-2024 16:59 is 18.77.

What is the 52-week high and low of Wanbury?

The 52-week high of Wanbury is ₹291.0 and the 52-week low is ₹91.00.

What is the TTM revenue of Wanbury?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Wanbury is ₹577.2 ( Cr.) .

About Wanbury Ltd

Wanbury was incorporated in 1990 as a private limited company under the name of Pearl Distributors Private Limited. The name of the company was changed to 'Pearl Organics Private Limited on January 17, 1991 and the company was converted into a public limited company on August 6, 1991.

Wanbury is the fastest growing pharma company amongst top 100 companies in India as per ORG-IMS has strong presence in domestic branded formulations. Wanburyâ€™s major thrust area also lies in Active Pharmaceutical Ingredient (API) and Contract Research and Manufacturing Services (CRAMS). It has a presence in Spain through its branded formulation business - Cantabria Pharma S. L acquired in 2006.

The company is having 3 API manufacturing facilities including 2 US FDA approved multi-product API facilities for regulated markets.

Product range of the company includes:

Coriminic table
Cpink table
Nock 2 tab
Senasof tab
Zevanuron
Rabiplus cap
Folinine
Cpink-s
Nuture
Adtrol 200mg

Milestones:

2008Wanbury opened an office in Zurich, Switzerland for its CRAMS business. Wanbury incorporated Wanbury Global FZE in Middle East for expanding its global business.Wanbury achieved consolidated turnover of Rs. 630 crore for 18 months period ended 30th September 2008. Rabiplus was awarded â€˜Best Brand Launchâ€™ by ORG-IMS as it did sales of Rs.13.8 crores in launch Year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.

2007Doctorâ€™s Organics Chemicals merged with Wanbury. Wanbury entered into a strategic association with Bravo Healthcare Wanbury incorporated Ningxia Wanbury Fine Chemicals Co to source raw materials from China. Wanbury approved as preferred Vendor by Pfizer (US) for Contract Research and Manufacturing Services (CRAMS). Cpink was awarded â€˜Best Brand Launchâ€™ by ORG-IMS as it did sales of Rs. 11 crores in launch year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.

2006Wanbury achieved 100 crore turnover. Pharmaceutical Products of India (PPIL) merged with Wanbury pursuant to BIFR order. Wanbury acquired Cantabria Pharma S.L. with presence in ethical branded formulations in the Spanish market. Wanbury crossed 1000 employees mark. Wanbury became the worldâ€™s largest producer of Metformin with production of 4500 MT.

2005Wanbury acquired Doctorâ€™s Organics and Chemicals, having a US FDA approved facility for manufacturing multi-product APIâ€™s.

2004Wander merged with Pearl Organics Limited and Pearl Organics renamed as Wanbury Wanbury set up its R & D center in Navi Mumbai for API. Wanbury started using SAP as a business transaction system.

2002Pearl Organics got US FDA approval for Patalganga plant.

1996Pearl Organics entered into a strategic alliance with Wyckoff Chemicals (US) to market its API in US.

1995Pearl Organics acquired plant of Brij Chemicals Pvt at Patalganga (Maharashtra).

1992Pearl Organics established its first plant in Tarapur for manufacturing APIâ€™s.

1991Pearl Distributors Pvt went public and was renamed as Pearl Organics.

1990Incorporated as Pearl Distributors Pvt

Achievements/ recognition:-

Wanbury ranks 47th as per ORG-IMS (Jan-2009)
Cpink awarded â€œBest Brand Launch' by ORG IMS (06-07)
Rabiplus awarded â€œBest Brand Launch' by ORG IMS (07-08)
World's largest producer of Metformin
Fastest growing company amongst top 100 companies in the domestic market as per ORG IMS.